title: Fat emulsions containing medium chain triglycerides in patients with sepsis syndrome: effects on pulmonary hemodynamics and gas exchange.
abstract: Fat emulsions containing medium chain triglycerides (MCT) have recently been introduced into clinical practice as a component of total parenteral nutrition. Since several authors reported increased pulmonary artery pressure and impaired gas exchange during intravenous (i.v.) fat use, in particular in septic patients, we studied the pulmonary hemodynamic and gas exchange effects of i.v. fat containing MCT and long chain triglycerides (LCT) in patients with sepsis syndrome. As the effects of fat emulsions have been attributed to increased formation of prostanoids, the production of thromboxane A2 and prostacyclin was investigated by the determination of urinary thromboxane B2 and 6-keto-prostaglandin F2 alpha, respectively. The i.v. fat use did not induce any alterations in pulmonary hemodynamics and gas exchange, the distribution of ventilation and perfusion nor urinary prostaglandin content. We conclude that fat emulsions containing MCT induce little alterations in pulmonary hemodynamics and gas exchange. This result is probably due to reduced prostaglandin formation because fat emulsions containing MCT provide less prostaglandin precursors than pure LCT emulsions.
authors.affiliation: Institut für Anaesthesiologie, Heinrich-Heine-Universität, Düsseldorf, FRG.
authors.forename: P
authors.initials: P
authors.lastname: Radermacher
authors.forename: B
authors.initials: B
authors.lastname: Santak
authors.forename: H
authors.initials: H
authors.lastname: Strobach
authors.forename: K
authors.initials: K
authors.lastname: Schrör
authors.forename: J
authors.initials: J
authors.lastname: Tarnow
mesh_terms: D000328:Adult; D000368:Aged; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine*; D005069:Evaluation Studies as Topic; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005989:Glycerides / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011652:Pulmonary Circulation / Q000187:drug effects*; D011659:Pulmonary Gas Exchange / Q000187:drug effects*; D018805:Sepsis / Q000503:physiopathology / Q000628:therapy* / Q000652:urine; D013929:Thromboxane B2 / Q000652:urine; D014280:Triglycerides / Q000008:administration & dosage / Q000627:therapeutic use*; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects
chemical_list: C078129:6-keto-prostaglandin F2alpha; D005217:Fat Emulsions, Intravenous; D005989:Glycerides; D014280:Triglycerides; D013929:Thromboxane B2; D015237:Dinoprost